Page last updated: 2024-12-08

methylnaphthazarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methylnaphthazarin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID271296
CHEMBL ID11475
SCHEMBL ID10409133
MeSH IDM0497044

Synonyms (29)

Synonym
1,4-naphthoquinone, 5,8-dihydroxy-2-methyl-
nsc-208732
NSC208732 ,
naphthazarin, 2-methyl-
ramentone
nsc114764
1, 5,8-dihydroxy-2-methyl-
nsc-114764
methylnaphthazarin
14554-09-7
2-methylnaphthazarin
smr000387073
MLS001048870 ,
sr-01000758993
SR-01000758993-2
CHEMBL11475
5,8-dihydroxy-2-methylnaphthalene-1,4-dione
SR-01000758993-3
YKPXIWHBRBFRQM-UHFFFAOYSA-N
1,4-naphthalenedione, 5,8-dihydroxy-2-methyl-
5,8-dihydroxy-2-methylnaphthoquinone #
bdbm33201
2-methyl-5,8-bis(oxidanyl)naphthalene-1,4-dione
cid_271296
SCHEMBL10409133
5,8-dihydroxy-2-methyl-1,4-naphthoquinone
AKOS030502544
DTXSID70297223
7-methylnaphthazarin
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.99530.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.17970.044717.8581100.0000AID485294; AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency8.89140.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.54810.125919.1169125.8920AID2549
LuciferasePhotinus pyralis (common eastern firefly)Potency23.93410.007215.758889.3584AID588342
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency9.39140.180013.557439.8107AID1460; AID1468
thioredoxin glutathione reductaseSchistosoma mansoniPotency0.63100.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency3.54810.707936.904389.1251AID504333
Bloom syndrome protein isoform 1Homo sapiens (human)Potency17.78280.540617.639296.1227AID2528
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency11.22020.036619.637650.1187AID2100
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency1.58490.01262.451825.0177AID485313
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency22.38720.010039.53711,122.0200AID1479
DNA polymerase betaHomo sapiens (human)Potency1.77830.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID1454
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency22.38720.65619.452025.1189AID463254
ras-related protein Rab-9AHomo sapiens (human)Potency1.12200.00022.621531.4954AID485297
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency0.79430.075215.225339.8107AID485360
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency28.18380.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency12.58930.251215.843239.8107AID504327
neuropeptide S receptor isoform AHomo sapiens (human)Potency5.01190.015812.3113615.5000AID1461
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency30.13130.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
protein quaking isoform 1Mus musculus (house mouse)IC50 (µMol)5.62101.61603.17105.6210AID488770
eukaryotic translation initiation factor 4 gamma 1 isoform 4Homo sapiens (human)IC50 (µMol)10.27001.150012.620025.6529AID855
eukaryotic translation initiation factor 4E isoform 1Mus musculus (house mouse)IC50 (µMol)10.27001.150012.620025.6529AID855
RevHuman immunodeficiency virus 1IC50 (µMol)75.42058.31208.92059.5290AID434976; AID488798
Female germline-specific tumor suppressor gld-1Caenorhabditis elegansIC50 (µMol)5.62751.47104.96148.4010AID2802; AID488797
Thioredoxin reductase 1, cytoplasmicRattus norvegicus (Norway rat)IC50 (µMol)0.70000.27201.82606.0000AID1503036
Thioredoxin reductase 1, cytoplasmicHomo sapiens (human)IC50 (µMol)2.40000.04322.26555.0000AID1503041
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glutathione S-transferase, partialHomo sapiens (human)EC50 (µMol)21.37001.512015.624446.8700AID1324
bcl-2-related protein A1 isoform 1Homo sapiens (human)EC50 (µMol)2.87001.23003.15506.5300AID1320
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
mesoderm formationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
signal transductionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell population proliferationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cellular oxidant detoxificationThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cell redox homeostasisThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
thioredoxin-disulfide reductase (NADPH) activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
identical protein bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
NADPH peroxidase activityThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
FAD bindingThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
fibrillar centerThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
nucleoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
extracellular exosomeThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
mitochondrionThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytosolThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
cytoplasmThioredoxin reductase 1, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1503034Cytotoxicity in human HEK293T cells assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503048Reduction in GSH/GSSG ratio in human HL60 cells at 1 to 5 uM incubated for 24 hrs by enzymatic recycling method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503040Inhibition of TrxR1 in human HL60 cells incubated for 12 hrs by TRFS-green dye based fluorescence assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503039Inhibition of NADPH-reduced rat glutathione reductase at 1 to 5 uM incubated for 1 hr in presence of NADPH and GSSG2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503045Induction of ROS production in human HL60 cells at 1 to 5 uM incubated for 1 hr by DCFH-DA staining based fluorescence assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503032Cytotoxicity in human A549 cells assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503062Induction of apoptosis in human HL60 cells 0.5 to 5 uM incubated for 24 hrs in presence of NAC by Annexin V/propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503026Cytotoxicity in HEK293T cells overexpressing TrxR1 (unknown origin) cells assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503061Induction of apoptosis in human HL60 cells 5 uM incubated for 24 hrs by Annexin V/propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503059Induction of apoptosis in human HL60 cells 1 uM incubated for 24 hrs by Annexin V/propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503031Cytotoxicity in human HepG2 cells assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503060Induction of apoptosis in human HL60 cells 3 uM incubated for 24 hrs by Annexin V/propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503042Cytotoxicity in HEK293T cells transfected with pIRESneo construct assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503043Cytotoxicity in human HeLa cells transfected with non targetting vector assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503054Cytotoxicity in human HL60 cells assessed as cell viability at 1 to 5 uM incubated for 48 hrs after 24 hrs pre-treatment with 50 uM BSO before compound addition by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503025Effect on TrxR1 protein expression in human HL60 cells at 1 to 5 uM incubated for 24 hrs by Western blot2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID363329Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID1503058Induction of apoptosis in human HL60 cells 0.5 uM incubated for 24 hrs by Annexin V/propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503027Cytotoxicity in human HL60 cells assessed as cell viability at 20 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503037Irreversible inhibition of NADPH-reduced rat TrxR1 assessed as suppression of DTNB reduction incubated for 1 hr followed by compound removal from incubation mixture by column desalting2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503063Induction of necrosis in human HL60 cells 5 uM incubated for 24 hrs by Annexin V/propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503056Induction of apoptosis in human HL60 cells assessed as increase in caspase-3 activity at 5 uM incubated for 24 hrs using Ac-DEVD-pNA substrate by colorimetric assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503055Induction of apoptosis in human HL60 cells assessed as increase in caspase-3 activity at 1 to 3 uM incubated for 24 hrs using Ac-DEVD-pNA substrate by colorimetric assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503044Cytotoxicity in human HeLa cells transfected with shTrxR1 assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503057Induction of apoptosis in human HL60 cells assessed as increase in condensed and fluorescent nuclei at 1 to 5 uM incubated for 24 hrs by Hoechst 33342 staining based phase contrast and fluorescence microscopy2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503033Cytotoxicity in human HeLa cells assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID189750Anticancer activity against Walker 256 carcinoma in rat after administration of 10 mg/kg; Activity expressed as % T/C (Active)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Design, synthesis and evaluation of novel 1,4-naphthoquinone derivatives as antifungal and anticancer agents.
AID189750Anticancer activity against Walker 256 carcinoma in rat after administration of 10 mg/kg; Activity expressed as % T/C (Active)2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Synthesis and evaluation of novel 1,4-naphthoquinone derivatives as antiviral, antifungal and anticancer agents.
AID363328Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID1503050Potentiation of H2O2-induced cytotoxicity in human HL60 cells assessed as induction of cell death at 1 uM incubated for 24 hrs by MTT assay (Rvb = 4%)2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503038Inhibition of NADPH-reduced rat TrxR1 U498C mutant assessed as suppression of DTNB reduction at 1 to 5 uM incubated for 1 hr2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503036Inhibition of NADPH-reduced rat TrxR1 assessed as suppression of DTNB reduction incubated for 1 hr2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503047Reduction in intracellular thiols in human HL60 cells at 1 to 5 uM incubated for 24 hrs by DTNB titration method2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503053Cytotoxicity in human HL60 cells assessed as cell viability at 1 to 5 uM incubated for 24 hrs after pre-treatment with 0.5 to 5 uM NAC before compound addition by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503049Cytotoxicity in human HL60 cells assessed as induction of cell death at 1 uM incubated for 24 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503035Cytotoxicity in human L02 cells assessed as reduction in cell viability at 1 to 5 uM incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503052Cytotoxicity in human HL60 cells assessed as cell viability at 1 to 5 uM incubated for 24 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503029Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503028Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503030Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by trypan blue dye exclusion assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503041Inhibition of TrxR1 in human HL60 cells incubated for 24 hrs by endpoint insulin reduction assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID1503046Induction of ROS production in human HL60 cells at 1 to 5 uM incubated for 1 hr by DHE staining based fluorescence assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
AID192093Anticancer activity against Walker 256 carcinoma cells in rat after administration of 10 mg/kg; Activity expressed as survivors out of 4 rats (Active)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Design, synthesis and evaluation of novel 1,4-naphthoquinone derivatives as antifungal and anticancer agents.
AID192093Anticancer activity against Walker 256 carcinoma cells in rat after administration of 10 mg/kg; Activity expressed as survivors out of 4 rats (Active)2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Synthesis and evaluation of novel 1,4-naphthoquinone derivatives as antiviral, antifungal and anticancer agents.
AID1503051Potentiation of H2O2-induced cytotoxicity in human HL60 cells assessed as induction of cell death at 3 uM incubated for 24 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]